Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.53 |
| ▸ | CKS1B | P61024 | 2/20 | 0.52 |
| ▸ | SKP1 | P63208 | 2/20 | 0.52 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.52 |
| ▸ | RET | P07949 | 8/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | WNT3A | P56704 | 1/20 | 0.45 |
| ▸ | PGK1 | P00558 | 1/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30888790 | 1.00 | GPR119 (0.53) | GPR119CKS1BSKP1SKP2RET | |
| SCHEMBL30112417 | 0.91 | GPR119 (0.44) | GPR119CKS1BSKP1SKP2RET | |
| SCHEMBL29197666 | 0.91 | GPR119 (0.44) | GPR119CKS1BSKP1SKP2RET | |
| SCHEMBL23301621 | 0.89 | GPR119 (0.54) | GPR119CKS1BSKP1SKP2ACHE | |
| SCHEMBL29197641 | 0.88 | GPR119 (0.40) | GPR119CKS1BSKP1SKP2RET | |
| SCHEMBL30112454 | 0.88 | GPR119 (0.40) | GPR119CKS1BSKP1SKP2RET | |
| SCHEMBL31583874 | 0.86 | GPR119 (0.48) | GPR119CKS1BSKP1SKP2RET | |
| SCHEMBL24670657 | 0.86 | GPR119 (0.42) | GPR119CKS1BSKP1SKP2PRMT5 | |
| SCHEMBL29990537 | 0.86 | GPR119 (0.42) | GPR119CKS1BSKP1SKP2PRMT5 | |
| SCHEMBL25074365 | 0.86 | RET (0.40) | GPR119CKS1BSKP1SKP2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4652161-A1 | 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS | Uppthera, Inc. (KR) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025077891-A1 | DEGRADATION AGENT COMPOUND TARGETING IRAK4, AND USE THEREOF | 江苏先声药业有限公司 | 2025-04-17 | — | — | WO | disclosed |
| US-20240343733-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | C4 THERAPEUTICS, INC. | 2024-10-17 | — | — | US | disclosed |
| EP-4434980-A1 | MULTIFUNCTIONAL COMPOUND CAPABLE OF DEGRADING BTK KINASE, AND COMPOSITION AND USE | Hangzhou HealZen Therapeutics Co., Ltd. (CN) | 2024-09-25 | — | — | EP | disclosed |
| CN-118598858-A | Multifunctional compound, composition and application of degradable BTK kinase | 杭州和正医药有限公司 | 2024-09-06 | — | — | CN | disclosed |
| US-20240287076-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | C4 THERAPEUTICS, INC. | 2024-08-29 | — | — | US | disclosed |
| WO-2024155112-A1 | 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS | UPPTHERA, INC. (KR) | 2024-07-25 | — | — | WO | disclosed |
| CN-116143757-B | Multifunctional compound, composition and application of degradable BTK kinase | 杭州和正医药有限公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-4367113-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | Biogen MA Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| CN-117940414-A | Compounds for targeting IRAK4 protein degradation | 渤健马萨诸塞州股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117771374-A | Application of NUDT1 in preparing medicine for treating MYC high expression or MYC amplified tumor | 武汉大学 | 2024-03-29 | — | — | CN | disclosed |
| EP-4333899-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2023088477-A1 | MULTIFUNCTIONAL COMPOUND CAPABLE OF DEGRADING BTK KINASE, AND COMPOSITION AND USE | 杭州和正医药有限公司 | 2023-05-25 | — | — | WO | disclosed |
| CN-116143757-A | Multifunctional compound, composition and application of degradable BTK kinase | 杭州和正医药有限公司 | 2023-05-23 | — | — | CN | disclosed |
| WO-2023283610-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | BIOGEN MA INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| WO-2022235945-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287076-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | GPR119 4531/4885CKS1B 611/4885SKP1 1257/4885 |
| US-20240343733-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | IRAK4, IRAK2, IRAK1 | GPR119 3162/4885CKS1B 969/4885SKP1 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.